Neck Ultrasound by Respiratory Physicians in Patients With Lung Cancer

Status Completed

Clinical Trial Summary

This is a study of routine neck ultrasound performed by respiratory physicians in patients with mediastinal lymphadenopathy and suspected lung cancer

Clinical Trial Description

In the first phase of the study a respiratory physician was trained to perform neck ultrasound and needle sampling of enlarged cervical lymph nodes according to preset criteria. In the second phase patients with suspected lung cancer and enlarged mediastinal lymph nodes underwent routine neck ultrasound and enlarged cervical lymph nodes were sampled using fine needle and or core needle biopsy.

The outcomes of interest in the study were the rate of malignant cervical lymphadenopathy defined as pathological evidence of cancer in neck lymph node samples consistent with a lung primary, adequacy of needle sampling, patient reported experience assessed by a visual analogue of discomfort associated with needle neck sampling and EBUS, and the proportion of patients that had nodal upstaging ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03970564
Study type	Observational
Source	University College Hospital Galway
Contact
Status	Completed
Phase
Start date	October 21, 2016
Completion date	May 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05452005` - Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer	Phase 1
Completed	`NCT03179150` - Clinical Validation of the M5L Lung CAD	N/A
Recruiting	`NCT03693339` - Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation	Phase 2
Completed	`NCT03184571` - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	Phase 2
Terminated	`NCT02308865` - Early Palliative Care in Metastatic Lung Cancer in Northern France	N/A
Not yet recruiting	`NCT03703596` - Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC	Phase 2
Terminated	`NCT04069936` - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC	Phase 2
Completed	`NCT04233476` - A Study of 99mTc-3PRGD2 Injection in Lung Cancer Patient	Phase 3
Recruiting	`NCT05537922` - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Active, not recruiting	`NCT04986670` - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer	N/A
Completed	`NCT03755102` - A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.	Early Phase 1
Not yet recruiting	`NCT03638765` - Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer	Phase 1
Recruiting	`NCT02976740` - SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy	Phase 2
Active, not recruiting	`NCT04085315` - Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer	Phase 1
Recruiting	`NCT03693326` - PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities	Phase 2
Recruiting	`NCT05860296` - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT04964960` - Pembro+Chemo in Brain Mets	Phase 2
Active, not recruiting	`NCT04973436` - DBT for Metastatic Lung Cancer	N/A
Recruiting	`NCT05078047` - Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO	Phase 3
Active, not recruiting	`NCT03057106` - Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC	Phase 2